Bendamustine Toxicity in FL Raises Eyebrows -- and Questions Bendamustine Toxicity in FL Raises Eyebrows -- and Questions
Results from the GALLIUM study in follicular lymphoma (FL) showed that fatal toxicity was higher with bendamustine compared with other regimens. What does this mean for clinical practice?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news
Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - June 16, 2016 Category: Pharmaceuticals Source Type: news
Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - June 16, 2016 Category: Pharmaceuticals Source Type: news
Response to 'Cure for Mantle Cell Lymphoma Within Reach'Response to 'Cure for Mantle Cell Lymphoma Within Reach'
Researchers not involved in the current research contest the characterization of bendamustine and rituximab as a "salvage" therapy, among other concerns. Letters to the Editor (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Rituximab Plus Bendamustine vs Standard Therapy for CLLRituximab Plus Bendamustine vs Standard Therapy for CLL
For patients with chronic lymphocytic leukemia (CLL), the combination of rituximab plus bendamustine was less effective than standard therapy, but it was also less toxic. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
First-line rituximab + bendamustine cost effective in advanced FL
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2016 Category: Drugs & Pharmacology Source Type: news
CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news
The U.S. Throws Out $3 Billion In Cancer Drugs Every Year
(Reuters Health) - U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and require doses adjusted based on the patient’s body size. Often, the packages contain much more medicine than patients need, and the leftovers wind up in the trash. Even when much of the medicine goes in the garbage, patients pay for the ...
Source: Science - The Huffington Post - March 28, 2016 Category: Science Source Type: news
FDA approves Roche’s Gazyva to treat follicular lymphoma
The US Food and Drug Administration (FDA) has granted approval for Roche's approved Gazyva (obinutuzumab) plus bendamustine chemotherapy, followed by Gazyva alone as a new treatment for people with follicular lymphoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2016 Category: Pharmaceuticals Source Type: news
FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Media News)
Source: Roche Media News - February 29, 2016 Category: Pharmaceuticals Source Type: news
FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 29, 2016 Category: Pharmaceuticals Source Type: news
FDA Okay for Obinutuzumab for Follicular LymphomaFDA Okay for Obinutuzumab for Follicular Lymphoma
The FDA has approved obinutuzumab to be used in combination with bendamustine as second-line treatment for follicular lymphoma. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 26, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
South San Francisco, CA -- February 26, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2016 Category: Drugs & Pharmacology Source Type: news
